Bairui granules versus Reyanning granules in adults with acute bronchitis: a multicenter, randomized, double-blind, double-dummy, comparative trial
Open Access
- 16 July 2026
- journal article
- clinical trial-article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1860478
Abstract
Background: Bairui granules, a monotherapy derived from Thesium chinense Turcz., are widely used in respiratory tract infections, yet high-quality clinical evidence for their effectiveness in acute bronchitis is lacking. Purpose: To evaluate the effectiveness and safety of Bairui granules in patients with acute bronchitis (Wind-heat invading lung syndrome). Study Design: The study (ChiCTR2200063906) was a multicenter, randomized, double-blind, double-dummy, comparative trial. Methods: Eligible participants from seven hospitals were randomized 2:1 to receive either Bairui granules plus placebo matching Reyanning Granules (experimental group) or Reyanning granules plus placebo matching Bairui Granules (control group) orally for 7 days. The primary endpoint was cough resolution rate after treatment. Secondary endpoints included time to cough and sputum resolution, area under the curve (AUC) for cough and sputum severity, bronchitis severity score (BSS), and traditional Chinese medicine (TCM) symptom scores. Results: Of 162 randomized patients, 161 completed the trial (107 experimental, 54 control). The cough resolution rate was higher in the experimental group than in the control group (72.22% vs. 35.19%; P < 0.0001). The time to cough resolution was 144 h (120,156) versus 168 h (138, 168) ( P = 0.001). AUC for cough severity was 184.3 versus 214.3 score·h ( P = 0.023). The BSS improvement at Day 9 was −4.82 (3.54) versus −4.30 (0.71) ( P = 0.068). The daytime cough TCM score improved by −6 (−6, −6) versus −6 (−6, −3) ( P = 0.003), and the sputum score improved by −3 (−6, −3) versus −3 (−3, −3) ( P = 0.031). Greater improvements were also observed in aversion to wind symptoms (Day 4) and sore throat symptoms (Day 9) in the experimental group. Adverse-event rates were similar between the two groups. All events were mild to moderate in severity and reversible. Conclusion: Bairui granules resulted in a higher cough-resolution rate and faster cough resolution than Reyanning granules in adults with acute bronchitis. The treatment was well tolerated. Clinical Trial Registration: https://www.chictr.org.cn/hvshowproject.html?id=193073&v=1.0 , identifier ChiCTR2200063906.Keywords
This publication has 17 references indexed in Scilit:
- CONSORT 2025 statement: updated guideline for reporting randomised trialsBMJ, 2025
- Changing the antibiotic prescribing of Australian general practice registrars’ for acute respiratory tract infections: a non-randomized controlled trialFamily Practice, 2025
- Effectiveness of Bairui granules in the treatment of respiratory tract infections: A systematic review and meta-analysisMedicine, 2024
- Systematic investigation of the material basis, effectiveness and safety of Thesium chinense Turcz. and its preparation Bairui Granules against lung inflammationChinese Medicine, 2024
- Chemistry of Bairui granules and its mechanisms in the protective effect against methotrexate-induced liver injuryPhytomedicine, 2023
- Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled TrialChinese Journal of Integrative Medicine, 2023
- Thesium chinense Turcz.: An ethnomedical, phytochemical and pharmacological reviewJournal of Ethnopharmacology, 2021
- Rhinovirus-Induced Rapidly Progressing ARDS in an Immunocompetent Host2019
- Antibiotics for acute bronchitisCochrane Database of Systematic Reviews, 2017
- Information Leaflet and Antibiotic Prescribing Strategies for Acute Lower Respiratory Tract InfectionJAMA, 2005